Altered TP53, CDKN2A, ATM, EPHA7, POT1, CHEK1, GRIN2A, and EGFR Predict Shorter Survival in Penile Squamous Cell Carcinoma
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
39694330
DOI
10.1016/j.modpat.2024.100689
PII: S0893-3952(24)00269-2
Knihovny.cz E-zdroje
- Klíčová slova
- human papillomavirus, next-generation sequencing, penile, squamous cell carcinoma, tumor mutational burden,
- MeSH
- ATM protein genetika MeSH
- dospělí MeSH
- erbB receptory genetika MeSH
- infekce papilomavirem MeSH
- inhibitor p16 cyklin-dependentní kinasy genetika MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nádorové biomarkery * genetika analýza MeSH
- nádorový supresorový protein p53 genetika MeSH
- nádory penisu * genetika mortalita patologie virologie MeSH
- prognóza MeSH
- proteiny vázající telomery MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- shelterinový komplex MeSH
- spinocelulární karcinom * genetika mortalita patologie virologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- ATM protein, human MeSH Prohlížeč
- ATM protein MeSH
- CDKN2A protein, human MeSH Prohlížeč
- EGFR protein, human MeSH Prohlížeč
- erbB receptory MeSH
- inhibitor p16 cyklin-dependentní kinasy MeSH
- nádorové biomarkery * MeSH
- nádorový supresorový protein p53 MeSH
- POT1 protein, human MeSH Prohlížeč
- proteiny vázající telomery MeSH
- shelterinový komplex MeSH
- TP53 protein, human MeSH Prohlížeč
Penile squamous cell carcinoma (pSCC) represents an uncommon malignancy characterized by stagnant mortality, psychosexual distress, and a highly variable prognosis. Currently, the World Health Organization distinguishes between human papillomavirus (HPV)-related and HPV-independent pSCC. Recently, there has been an evolving line of research documenting the enrichment of HPV-independent pSCC with a high tumor mutational burden (TMB) and programmed death ligand-1 expression, as well as clusters of genes associated with HPV status. In this study, we conducted comprehensive next-generation sequencing DNA profiling of 146 pSCC samples using a panel consisting of 355 genes associated with tumors. This profiling was correlated with immunohistochemical markers and prognostic clinical data. A survival analysis of recurrent genomic events (found in ≥10 cases) was performed. TP53, CDKN2A, ATM, EPHA7, POT1, CHEK1, GRIN2A, and EGFR alterations were associated with significantly shortened overall survival in univariate and multivariate analysis. HPV positivity, diagnosed through both p16 immunohistochemistry and HPV DNA analysis, displayed no impact on survival but was associated with high-grade, lymphatic invasion, programmed death ligand-1 negativity/weak expression, and low TMB. FAT1, TP53, CDKN2A, CASP8, and HRAS were more often mutated in HPV-independent pSCC. In contrast, HPV-associated pSCCs were enriched by EPHA7, ATM, GRIN2A, and CHEK1 mutations. PIK3CA, FAT1, FBXW7, and KMT2D mutations were associated with high TMB. NOTCH1, TP53, CDKN2A, POT1, KMT2D, ATM, CHEK1, EPHA3, and EGFR alterations were related to adverse clinicopathologic signs, such as advanced stage, high tumor budding, and lymphovascular invasion. We detected 160 alterations with potential treatment implications, with 21.2% of samples showing alterations in the homologous recombination repair pathway. To the best of our knowledge, this study describes the largest cohort of pSCC with complex molecular pathologic, clinical, and prognostic analysis correlating with prognosis.
Citace poskytuje Crossref.org
